GlassScriptPhysician profile
Elizabeth Mohr
NPI 1447425418
$4,863.43
in general payments reported to CMS, 2019-2025
35 companies · $1,381 in 2025
The $1,381 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $199 · 2020: $301 · 2021: $359 · 2022: $551 · 2023: $817 · 2024: $1,256 · 2025: $1,381.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,434 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,434.09 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $541.84 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $464.05 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Shield Therapeutics INC | $373.38 | 2023-2025 | Accrufer |
| Takeda Pharmaceuticals U.S.A., INC. | $358.09 | 2019-2022 | |
| Novo Nordisk INC | $346.33 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbott Laboratories | $282.71 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Bayer Healthcare Pharmaceuticals INC. | $274.78 | 2021-2025 | |
| Lilly USA, LLC | $229.52 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Glaxosmithkline, LLC. | $224.01 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $219.89 | 2020-2025 | |
| Otsuka America Pharmaceutical, INC. | $174.34 | 2023-2025 | Rexulti, Jynarque |
| Sumitomo Pharma America, INC. | $161.55 | 2023-2025 | Gemtesa |
| Calliditas Therapeutics US INC. | $129.38 | 2022-2025 | Tarpeyo |
| Lundbeck LLC | $121.14 | 2023-2025 | Rexulti, Vyepti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $111.40 | 2024-2025 | Caplyta |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $93.63 | 2024-2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $91.53 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Endo Pharmaceuticals INC. | $73.52 | 2020-2021 | |
| Esperion Therapeutics, INC. | $64.11 | 2021-2025 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.49 | 2019-2023 | Jardiance |
| Idorsia Pharmaceuticals US INC | $61.30 | 2023-2025 | Quviviq, Quviviq |
| Astellas Pharma US INC | $59.95 | 2019-2025 | Veozah |
| Amgen INC. | $54.82 | 2019-2022 | |
| Alnylam Pharmaceuticals INC. | $54.05 | 2022-2024 | Givlaari |
| Axsome Therapeutics, INC. | $33.53 | 2025 | Auvelity |
| Tactile Systems Technology INC | $26.63 | 2024 | Flexitouch Plus, Entre Plus |
| Ultragenyx Pharmaceutical INC. | $25.85 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $25.51 | 2022 | |
| Ardelyx, INC. | $25.00 | 2024 | Ibsrela |
| Biohaven Pharmaceuticals, INC. | $19.52 | 2021 | |
| Gilead Sciences, INC. | $19.43 | 2025 | |
| Novartis Pharmaceuticals Corporation | $17.92 | 2019 | |
| Sonex Health, INC. | $16.59 | 2023 | Sx-One Microknife |
| Allergan, INC. | $13.20 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $12.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Mohr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.